Confronto

Efinopegdutide vs. Eloralintide

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Metabolico

N. CAS

2055640-93-0

nessun dato

Peso molecolare

nessun dato

Emivita

115 h

nessun dato

Sequenza

modifiziertes, von Oxyntomodulin abgeleitetes Peptid, konjugiert an ein humanes IgG4-Fragment (Verlängerung der Plasma-Halbwertszeit)

nessun dato

Meccanismo d'azione

Efinopegdutide

Efinopegdutide is an oxyntomodulin-derived peptide acting as a dual agonist at the GLP-1 and glucagon receptors with a relative potency of approximately 2:1 (GLP-1 to glucagon). The GLP-1 component mediates glucose-dependent insulin secretion and modulation of satiety; the glucagon component increases energy expenditure and hepatic fat oxidation, which is proposed to contribute to the observed reduction in liver fat. Conjugation to an IgG4 fragment prolongs the half-life and enables weekly administration.

Eloralintide

Eloralintide selectively activates amylin receptors (preferentially AMY1R) and promotes satiety. The approach targets weight loss via the amylin axis, complementary to or independent of GLP-1 agents.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Efinopegdutide	Eloralintide
Germania	Non approvato	Non approvato
Stati Uniti	Non approvato	Non approvato

Voci complete

Frequently asked questions

What is the difference between Efinopegdutide and Eloralintide?: Efinopegdutide is classified as "Metabolico", while Eloralintide is classified as "Metabolico". Efinopegdutide: Efinopegdutide (MK-6024, formerly JNJ-64565111 / HM12525A) is a once-weekly dual agonist at the GLP-1 and glucagon receptors, developed by Hanmi and Merck. It has been studied for obesity and notably for metabolic liver disease (MASH/NAFLD); a phase-2 trial showed greater liver-fat reduction than semaglutide. Investigational, not approved. Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Efinopegdutide or Eloralintide?: The highest available evidence level is "RCT sull'uomo" for Efinopegdutide and "RCT sull'uomo" for Eloralintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Efinopegdutide and Eloralintide in Germany and the United States?: Germania: Efinopegdutide — Non approvato, Eloralintide — Non approvato. Stati Uniti: Efinopegdutide — Non approvato, Eloralintide — Non approvato. These are factual summaries with source and review date on the individual pages.

Country

Efinopegdutide

Eloralintide

Germania

Non approvato

Stati Uniti

Non approvato

Frequently asked questions

What is the difference between Efinopegdutide and Eloralintide?

Efinopegdutide is classified as "Metabolico", while Eloralintide is classified as "Metabolico". Efinopegdutide: Efinopegdutide (MK-6024, formerly JNJ-64565111 / HM12525A) is a once-weekly dual agonist at the GLP-1 and glucagon receptors, developed by Hanmi and Merck. It has been studied for obesity and notably for metabolic liver disease (MASH/NAFLD); a phase-2 trial showed greater liver-fat reduction than semaglutide. Investigational, not approved. Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Efinopegdutide or Eloralintide?

The highest available evidence level is "RCT sull'uomo" for Efinopegdutide and "RCT sull'uomo" for Eloralintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Efinopegdutide and Eloralintide in Germany and the United States?

Germania: Efinopegdutide — Non approvato, Eloralintide — Non approvato. Stati Uniti: Efinopegdutide — Non approvato, Eloralintide — Non approvato. These are factual summaries with source and review date on the individual pages.